NCT02605993View on ClinicalTrials.gov

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 4, 2016

Primary Completion Date

February 23, 2017

Study Completion Date

January 12, 2022

Conditions
Paroxysmal Nocturnal HemoglobinuriaPNH
Interventions
BIOLOGICAL

Ravulizumab

All treatments were given as IV infusions.

Trial Locations (16)

10048

Clinical Trial Site, Taipei

28040

Clinical Trial Site, Madrid

28220

Clinical Trial Site, Majadahonda

45147

Clinical Trial Site, Essen

52074

Clinical Trial Site, Aachen

59037

Clinical Trial Site, Lille

69495

Clinical Trial Site, Lyon

75475

Clinical Trial Site, Paris

89081

Clinical Trial Site, Ulm

M4N 3M5

Clinical Trial Site, Toronto

03080

Clinical Trial Site, Seoul

03722

Clinical Trial Site, Seoul

08916

Clinical Trial Site, Badalona

08036

Clinical Trial Site, Barcelona

LS9 7TF

Clinical Trial Site, Leeds

SE5 9RS

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY